The role of soluble CD40L in immunosuppression

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Schlom, Jeffrey ^a   Jochems, Caroline ^a   Gulley, James L ^a   Huang, Jianping ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunosuppression; Myeloid derived suppressor cells (MDSC); Regulatory T cells (Tregs); scd40l; Vaccine therapy

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; CLOPIDOGREL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; RILIMOGENE GALVACIREPVEC; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL EXPANSION; CYTOKINE RELEASE; DRUG RESPONSE; HUMAN; IMMUNOMODULATION; INTRACELLULAR SIGNALING; LUNG CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; THROMBOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 84886944364     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22546     Document Type: Article

References (10)

1. Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, et al. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res 2004; 10:610-4; PMID:14760083; http://dx.doi.org/10.1158/1078-0432.CCR-0348-03.
2. Osada J, Rusak M, Kamocki Z, Dabrowska MI, Kedra B. Platelet activation in patients with advanced gastric cancer. Neoplasma 2010; 57:145-50; PMID:20099978; http://dx.doi.org/10.4149/neo_2010_02_145.
3. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 2012; 120:3030-8; PMID:22932804; http:// dx.doi.org/10.1182/blood-2012-05-427799.
4. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-105; PMID:20100959; http://dx.doi. org/10.1200/JCO.2009.25.0597.
5. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74; PMID:19890632; http://dx.doi. org/10.1007/s00262-009-0782-8.
6. Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005; 173:790- PMID:15711271; http://dx.doi.org/10.1097/01. ju.0000147013.09157.8e.
7. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16:3100-4; PMID:20421432; http://dx.doi.org/10.1158/1078-0432.CCR-09-2891.
8. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008; 14:3536-44; PMID:18519787; http://dx.doi. org/10.1158/1078-0432.CCR-07-4025.
9. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi. org/10.1126/science.1129139.
10. Azar RR, Kassab R, Zoghbi A, Aboujaoudé S, El-Osta H, Ghorra P, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151:521.e1-521.e4; PMID:16442924; http://dx.doi.org/10.1016/j.ahj.2005.10.021.